Progenics begins search process to identify new board candidates
Progenics Pharmaceuticals announced that, based on the preliminary voting results of its 2019 Annual Meeting of Shareholders, Progenics directors Mark Baker, Bradley Campbell, Karen Ferrante, David Scheinberg and Nicole Williams received a majority of the votes cast at the Annual Meeting, and Peter Crowley and Michael Kishbauch did not. In accordance with Progenics' bylaws, Crowley and Kishbauch have each submitted a contingent resignation which will become effective only if the certification of the votes of the Annual Meeting confirms that they did not receive a majority of the votes cast and the Board of Directors accepts the resignation. As required under the Company's bylaws, the Nominating and Corporate Governance Committee is considering these matters and will recommend to the Board the action to be taken with respect to the tendered contingent resignations. The Board will determine whether to accept such resignations, or what other action should be taken, in accordance with Progenics' bylaws.The Company also announced that the Board has retained Korn Ferry to help identify new Board candidates with relevant business, commercial and development experience.